STOCK TITAN

Cadrenal Therapeutics, Inc. - $CVKD STOCK NEWS

Welcome to our dedicated page for Cadrenal Therapeutics news (Ticker: $CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cadrenal Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cadrenal Therapeutics's position in the market.

Rhea-AI Summary
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) has engaged The Sage Group to explore strategic partnerships, co-development, and licensing agreements for tecarfarin, a novel oral and reversible anticoagulant. Tecarfarin addresses the need for stable anticoagulation in patients with certain orphan diseases, including ESKD with AFib, LVADs, and APS. The drug has shown promising results in clinical trials and has been granted orphan drug and fast-track designations by the FDA. Cadrenal estimates the combined addressable market opportunity to be in excess of US $2 billion per year in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
-
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) announced their CEO, Quang Pham, will present at NobleCon19, discussing their late-stage novel oral anticoagulant tecarfarin designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare medical conditions. The presentation will be available via high-definition video webcast on the company's website and other platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
conferences
-
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) provided a corporate update on tecarfarin, a novel oral anticoagulant designed to prevent heart attacks, strokes, and deaths due to blood clots. Tecarfarin's expanded focus includes rare medical conditions such as ESKD with AFib, LVADs, and APS, representing a market opportunity of over $2 billion annually in the U.S. The company also highlighted the need for a new VKA at the recent European Society of Cardiology Congress and completed a $7.5 million private placement. Q3 2023 operating expenses totaled $989,000, with $628,000 cash used in operating activities. Cash balances were $9.1 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.38%
Tags
Rhea-AI Summary
The 26th BioFlorida Annual Conference highlighted the growth and success of Florida's life sciences industry. The conference featured discussions on various topics including medical innovations, advancements in neurodegeneration, and financing insights. BioFlorida also announced a strategic partnership with BIOQuébec. The conference recognized individuals and organizations for their achievements and presented awards in different categories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
-
Rhea-AI Summary
Cadrenal Therapeutics to participate in investor conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
conferences
-
Rhea-AI Summary
Cadrenal Therapeutics is developing tecarfarin, a late-stage novel oral and reversible anticoagulant designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with certain rare medical conditions. Recent data from the FRAIL-AF trial presented at the European Society of Cardiology Congress suggests that switching from a VKA to a NOAC in frail older patients with AFib may lead to more bleeding complications without reducing thromboembolic complications. Cadrenal believes tecarfarin can address this unmet need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
none
Rhea-AI Summary
Cadrenal Therapeutics expands evaluation of tecarfarin for antiphospholipid syndrome, a rare medical condition affecting 167,000 patients in the US. Tecarfarin aims to provide improved outcomes compared to warfarin. Market opportunity for tecarfarin in rare medical conditions exceeds $2 billion per year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
none
-
Rhea-AI Summary
Cadrenal Therapeutics to participate in the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.37%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
none
Cadrenal Therapeutics, Inc.

Nasdaq:CVKD

CVKD Rankings

CVKD Stock Data

7.36M
8.02M
46.72%
3.45%
0.26%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
PONTE VEDRA